Poster Display session 2 Poster Display session

1003P - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers (ID 2844)

Presentation Number
1003P
Lecture Time
12:00 - 12:00
Speakers
  • S.Intidhar Labidi-Galy (Geneva, Switzerland)
Session Name
Poster Display session 2
Location
Poster Area (Hall 4), Fira Gran Via, Barcelona, Spain
Date
29.09.2019
Time
12:00 - 13:00

Abstract

Background

To investigate clinical factors associated with prolonged progression-free survival (PFS) and overall survival (OS) in relapsing epithelial ovarian cancer (EOC) patients with BRCA mutations and receiving olaparib as maintenance therapy in real-world.

Methods

Multicenter (8 hospitals) European retrospective study of relapsing EOC patients having germline or somatic mutations of BRCA1/BRCA2 genes and treated with olaparib as maintenance therapy after platinum-based chemotherapy.

Results

One hundred and fifteen patients were included. Median age was 54 years. There were 90 BRCA1 carriers, 24 BRCA2 carriers and one patient had germline mutation of BRCA1 and BRCA2. Six patients had somatic mutations (all BRCA1) and 109 had germline mutations. Ninety percent had serous carcinomas and were platinum-sensitive. Following ultimate platinum-based chemotherapy, 69% of the patients had normalization of CA-125 levels and 87% had RECIST objective responses, either partial (53%) or complete (34%). After a median follow-up of 21 months, median PFS was 12.7 months and median OS was 35.4 months. In multivariate analysis, factors associated with prolonged PFS under olaparib were: platinum-free interval (PFI) ≥ 12 months, RECIST complete response (CR) or partial response (PR) and normalization of CA-125 upon ultimate platinum-based chemotherapy. Factors associated with prolonged OS were PFI ≥ 12 months, CR and normalization of CA-125.

Conclusions

Platinum-free interval ≥ 12 months, complete response and normalized CA-125 levels after ultimate platinum-based chemotherapy are associated with prolonged PFS and OS in relapsing BRCA mutated ovarian cancer patients who received olaparib as maintenance therapy.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S.I. Labidi-Galy: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. T. de La Motte Rouge: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. O. Derbel: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. A. Wolfer: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. E. Kalbacher: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. O. Tredan: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. V. Heinzelmann-Schwarz: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. F. Bazan: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. M. Rodrigues: Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca. I.L. Ray-Coquard: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca. All other authors have declared no conflicts of interest.

Collapse